搜索结果

Search Results for " cdk-4/6-in-6 "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T39957	CDK4/6-IN-6	CDK	Cell Cycle/Checkpoint
	CDK4/6-IN-6 是CDK4/CDK6的有效抑制剂，结合CDK4/Cyclin D1 和 CDK6/Cyclin D3 的 Ki 为 0.6 nM 和 13.9 nM。
T10736	CDK4/6-IN-2	CDK	Cell Cycle/Checkpoint
	CDK4/6-IN-2 是一种CDK4和CDK6抑制剂，IC50分别为 2.7 和 16 nM。
T10738	Abemaciclib metabolite M20 CDK4/6-IN-4,LSN3106726	CDK	Cell Cycle/Checkpoint
	Abemaciclib metabolite M20 (CDK4/6-IN-4) 是 Abemaciclib 的活性代谢物。 Abemaciclib metabolite M20 是一种特异性 CDK4/6 抑制剂，可用于癌症治疗的相关研究。
T14918	CDK9-IN-2 N2'-(反式-4-氨基环己基)-5'-氯-N6-[(3-氟苯基)甲基]-[2,4'-联吡啶]-2',6-二胺	Others; CDK	Cell Cycle/Checkpoint; Others
	CDK9-IN-2 是一种特异性CDK9抑制剂。它在 A2058 皮肤细胞系（72 小时）和 H929 多发性骨髓瘤细胞系（72小时）的IC50分别为 7 nM 和 5 nM。
T10737	CDK4/6-IN-3	CDK	Cell Cycle/Checkpoint
	CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.
T39956	CDK4/6-IN-5 CDK4/6-IN-5
	CDK4/6-IN-5 is a highly effective inhibitor of CDK4 and CDK6, with Ki values of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively (WO2019207463A1, example A93).
T61583	CDK/HDAC-IN-1
	CDK/HDAC-IN-1 exhibits potent inhibitory activity towards CDK2/4/6 and HDAC6, with IC50 values of 60.9 ± 2.9 nM, 276 ± 22.3 nM, 27.2 ± 4.2 nM, and 128.6 ± 0.4 nM, respectively.
T36967	LSN3106729 hydrochloride
	LSN3106729 hydrochloride, the metabolite of Abemaciclib , is a CDK inhibitor with antitumor activity. LSN3106729 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader[1]. [1]. Edward S. Kim, et al. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. [2]. Nathanael Gray, et al. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods o...
T72951	CDK4/6-IN-14
	CDK4/6-IN-14 是一种有效且高度选择性的 CDK4和 CDK6(CDK) 抑制剂，IC50分别为 10 nM 和 16 nM。CDK4/6-IN-14 的选择性是 CDK1、2、7 和 9 的 60 多倍，并且在其他 205 种激酶中表现出高选择性。